Scarica l'app Stockscreener
19.31
0.36%
-0.07
Dopo l'orario di chiusura:
19.41
0.10
+0.52%
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World
Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times
Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com
FDA Grants Special Protocol Assessment for Cartesian's Myasthenia Gravis Treatment - StockTitan
Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World
Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha
Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat
Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks
Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Myasthenia Gravis Market Poised for Significant Growth from - openPR
Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat
Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Awards Stock Options to New Employees in Retention Move - StockTitan
Barclays PLC Purchases 7,849 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33% - Simply Wall St
Critical Review: Cartesian Therapeutics (RNAC) vs. The Competition - Defense World
State Street Corp Has $2.54 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) Trading 7.2% HigherStill a Buy? - MarketBeat
Cartesian Therapeutics ATM - Leerink Partners
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - Defense World
Cartesian therapeutics director Timothy Springer buys $965k in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics director Timothy Springer buys $965k in stock - Investing.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):